CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $55.72, moving -1.83% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.26%. On ...

Tue, March 17, 2026 at 4:16 PM UTC The catalyst behind Piper Sandler's revised target is a freshly issued $600M convertible note due March 2031, convertible at $76.56 per share with an effective ...

CRISPR Therapeutics CRSP and Beam Therapeutics BEAM are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...

The average one-year price target for CRISPR Therapeutics (NasdaqGM:CRSP) has been revised to $82.91 / share. This is an increase of 14.61% from the prior estimate of $72.34 dated January 11, 2026.

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even come ...

We recently published These 10 Stocks Surprisingly Lead Gains While Wall Street Naps. CRISPR Therapeutics AG (NASDAQ:CRSP) is one of this week’s top performers. CRISPR Therapeutics soared by 18.22 ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $551 million as of Q4 2025. The gene-editing company remains on ...